Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models
| dc.contributor.author | PUJATTI, PRISCILLA B. | |
| dc.contributor.author | FOSTER, JULIE M. | |
| dc.contributor.author | FINUCANE, CIARA | |
| dc.contributor.author | HUDSON, CHANTELLE D. | |
| dc.contributor.author | BURNET, JEROME C. | |
| dc.contributor.author | PASQUALOTO, KERLY F.M. | |
| dc.contributor.author | MENGATTI, JAIR | |
| dc.contributor.author | MATHER, STEPHEN J. | |
| dc.contributor.author | ARAUJO, ELAINE B. de | |
| dc.contributor.author | SOSABOWSKI, JANE K. | |
| dc.coverage | Internacional | pt_BR |
| dc.date.accessioned | 2015-01-06T13:07:30Z | |
| dc.date.available | 2015-01-06T13:07:30Z | |
| dc.date.issued | 2015 | pt_BR |
| dc.description.abstract | We evaluated and compared a new bombesin analog [Tyr–Gly5, Nle14]-BBN(6–14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTApeptide to PC-3 cells was observed. Both peptides could | |
| dc.format.extent | 91-101 | pt_BR |
| dc.identifier.citation | PUJATTI, PRISCILLA B.; FOSTER, JULIE M.; FINUCANE, CIARA; HUDSON, CHANTELLE D.; BURNET, JEROME C.; PASQUALOTO, KERLY F.M.; MENGATTI, JAIR; MATHER, STEPHEN J.; ARAUJO, ELAINE B. de; SOSABOWSKI, JANE K. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. <b>Applied Radiation and Isotopes</b>, v. 96, p. 91-101, 2015. DOI: <a href="https://dx.doi.org/10.1016/j.apradiso.2014.11.006">10.1016/j.apradiso.2014.11.006</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/23226. | |
| dc.identifier.doi | 10.1016/j.apradiso.2014.11.006 | |
| dc.identifier.issn | 0969-8043 | pt_BR |
| dc.identifier.orcid | https://orcid.org/0000-0003-0456-5589 | |
| dc.identifier.percentilfi | 35.56 | |
| dc.identifier.uri | http://repositorio.ipen.br/handle/123456789/23226 | |
| dc.identifier.vol | 96 | pt_BR |
| dc.relation.ispartof | Applied Radiation and Isotopes | pt_BR |
| dc.rights | openAccess | pt_BR |
| dc.subject | radiopharmaceuticals | |
| dc.subject | dtpa | |
| dc.subject | labelled compounds | |
| dc.subject | indium 111 | |
| dc.subject | neoplasms | |
| dc.subject | peptides | |
| dc.subject | impurities | |
| dc.subject | comparative evaluations | |
| dc.title | Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models | pt_BR |
| dc.type | Artigo de periódico | pt_BR |
| dspace.entity.type | Publication | |
| ipen.autor | ELAINE BORTOLETI DE ARAUJO | |
| ipen.autor | JAIR MENGATTI | |
| ipen.autor | PRISCILLA BRUNELLI PUJATTI | |
| ipen.codigoautor | 664 | |
| ipen.codigoautor | 1498 | |
| ipen.codigoautor | 6795 | |
| ipen.contributor.ipenauthor | ELAINE BORTOLETI DE ARAUJO | |
| ipen.contributor.ipenauthor | JAIR MENGATTI | |
| ipen.contributor.ipenauthor | PRISCILLA BRUNELLI PUJATTI | |
| ipen.date.recebimento | 14-12 | pt_BR |
| ipen.identifier.fi | 1.136 | pt_BR |
| ipen.identifier.ipendoc | 20274 | pt_BR |
| ipen.identifier.ods | 3 | |
| ipen.range.fi | 0.001 - 1.499 | |
| ipen.range.percentilfi | 25.00 - 49.99 | |
| ipen.type.genre | Artigo | |
| relation.isAuthorOfPublication | ca74886d-6974-47a8-9308-c4cc39bb6e35 | |
| relation.isAuthorOfPublication | 4722b83e-1d23-488f-b497-6a72d3048679 | |
| relation.isAuthorOfPublication | 9ea38f67-2c4c-445a-b2f8-4f05edf0ff29 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9ea38f67-2c4c-445a-b2f8-4f05edf0ff29 | |
| sigepi.autor.atividade | PUJATTI, PRISCILLA B.:6795:-1:S | |
| sigepi.autor.atividade | MENGATTI, JAIR:1498:110:N | |
| sigepi.autor.atividade | ARAUJO, ELAINE B. DE:664:110:N |